Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Inflazyme initiates phase I clinical trials with IPL-576092

June 4, 1999

Dual TxA2 and PGD2 antagonists from Shionogi

June 4, 1999

New PDE4 inhibitors with reduced emetogenic potential in the Kyowa Hakko pipeline

June 3, 1999

Sepracor and UCB reach Zyrtec isomer licensing agreement

June 3, 1999

Cell Therapeutics terminates enrollment in lung injury trial of lisofylline

June 2, 1999

Aradigm and Genentech sign development agreement for cystic fibrosis therapy

June 2, 1999

PathoGenesis signs European distribution agreements and launches TOBI in two new markets

June 1, 1999

Improved PDE4 inhibitors in development at Merck Frosst

May 26, 1999

Muscarinic antagonists from Tokyo Tanabe particularly useful for respiratory disorders

May 25, 1999

Yoshitomi reports potent and selective tryptase inhibitors with oral activity

May 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...